132 related articles for article (PubMed ID: 35006369)
1. Co-overexpression of TRAIL and Smac sensitizes MDA-MB-231 cells to radiation through apoptosis depending on mitochondrial pathway.
Xu W; Fang F; Wang Y; Qin L; Han Y; Huang Y; Li B; Liu Y; Wang Z
Radiat Environ Biophys; 2022 Mar; 61(1):37-48. PubMed ID: 35006369
[TBL] [Abstract][Full Text] [Related]
2. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.
Guo F; Nimmanapalli R; Paranawithana S; Wittman S; Griffin D; Bali P; O'Bryan E; Fumero C; Wang HG; Bhalla K
Blood; 2002 May; 99(9):3419-26. PubMed ID: 11964312
[TBL] [Abstract][Full Text] [Related]
3. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
4. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
5. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
Fandy TE; Shankar S; Srivastava RK
Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
[TBL] [Abstract][Full Text] [Related]
6. Conditionally replicating adenovirus combined with gene-targeted radiotherapy induces apoptosis via TRAIL death receptors in MDA-MB-231 cells.
Wu JH; Wang HF; Wang ZC; Xu K; Qi YL; Li JH; Gong SL; Liu Y; Liu Y
Mol Med Rep; 2013 Jul; 8(1):299-305. PubMed ID: 23708314
[TBL] [Abstract][Full Text] [Related]
7. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
9. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
[TBL] [Abstract][Full Text] [Related]
10. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
11. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.
Han J; Goldstein LA; Gastman BR; Rabinowich H
J Biol Chem; 2006 Apr; 281(15):10153-63. PubMed ID: 16478725
[TBL] [Abstract][Full Text] [Related]
12. TRAIL overexpression co-regulated by Egr1 and HRE enhances radiosensitivity of hypoxic A549 cells depending on its apoptosis inducing role.
Yang YM; Fang F; Li X; Yu L; Wang ZC
Oncol Rep; 2017 Jan; 37(1):533-539. PubMed ID: 27878298
[TBL] [Abstract][Full Text] [Related]
13. Induction of interferon-β and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells.
Granqvist V; Holmgren C; Larsson C
PLoS One; 2021; 16(3):e0248175. PubMed ID: 33770100
[TBL] [Abstract][Full Text] [Related]
14. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
15. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
16. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.
Khorashadizadeh M; Soleimani M; Khanahmad H; Fallah A; Naderi M; Khorramizadeh M
Tumour Biol; 2015 Jun; 36(6):4213-21. PubMed ID: 25586349
[TBL] [Abstract][Full Text] [Related]
17. Effect of Smac on TRAIL-induced apoptosis of prostate cancer cell line PC-3 and the molecular mechanism.
Wang M; Huang T; Zeng F; Jiang G; Wang L; Zheng L; Tong Q
J Huazhong Univ Sci Technolog Med Sci; 2012 Apr; 32(2):233-236. PubMed ID: 22528226
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.
Deng Y; Lin Y; Wu X
Genes Dev; 2002 Jan; 16(1):33-45. PubMed ID: 11782443
[TBL] [Abstract][Full Text] [Related]
19. Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis.
Szliszka E; Zydowicz G; Mizgala E; Krol W
Int J Oncol; 2012 Sep; 41(3):818-28. PubMed ID: 22735465
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
